<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734913</url>
  </required_header>
  <id_info>
    <org_study_id>ZSP1602-16-01</org_study_id>
    <nct_id>NCT03734913</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of ZSP1602 in Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Zhongsheng Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Zhongsheng Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and&#xD;
      determine the maximum tolerated dose of ZSP1602 in participants with basal cell carcinoma,&#xD;
      adenocarcinoma of esophagogastric junction, small cell lung cancer, neuroendocrine neoplasm&#xD;
      and other advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting Toxicity (DLT)</measure>
    <time_frame>At day 32 after first dosing.</time_frame>
    <description>To determine the DLT of ZSP1602 in advanced solid tumor participants accessed by CTCAE4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>At day 32 after first dosing.</time_frame>
    <description>The highest dose at the level with &lt;= 2/6 participants experienced DLT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>From Screening, Day 28 of Cycle1 (28 days), then every 8 weeks, until disease progression or discontinuation from study (approximately 18 months or earlier if participants terminate from the study).</time_frame>
    <description>For Part1 and Part2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Over all response (ORR)</measure>
    <time_frame>From Screening, Day 28 of Cycle1 (28 days), then every 8 weeks, until disease progression or discontinuation from study (approximately 18 months or earlier if participants terminate from the study).</time_frame>
    <description>For Part1 and Part2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ZSP1602</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (4 days) and 1 (28 days) of treatment per participants.</time_frame>
    <description>For Part1 and Part2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ZSP1602</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (4 days) and 1 (28 days) of treatment per participants.</time_frame>
    <description>For Part1 and Part2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of ZSP1602</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (4 days) and 1 (28 days) of treatment per participants.</time_frame>
    <description>For Part1 and Part2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of ZSP1602</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (4 days) and 1 (28 days) of treatment per participants.</time_frame>
    <description>For Part1 and Part2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of ZSP1602</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (4 days) and 1 (28 days) of treatment per participants.</time_frame>
    <description>For Part1 and Part2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl/F of ZSP1602</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (4 days) and 1 (28 days) of treatment per participants.</time_frame>
    <description>For Part1 and Part2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <condition>Medulloblastoma</condition>
  <condition>Adenocarcinoma of Esophagogastric Junction</condition>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Neuroendocrine Neoplasm</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced solid tumors including basal cell carcinoma and medulloblastoma, regardless of SMO or Gli1 alteration status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Adenocarcinoma of Esophagogastric Junction with SMO or Gli1 protein overexpression alteration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with basal cell carcinoma, small cell lung cancer, neuroendocrine neoplasm and glioblastoma with SMO or Gli1 protein overexpression alteration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1602</intervention_name>
    <description>ZSP1602 capsules for oral administration</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2 Cohort A</arm_group_label>
    <arm_group_label>Part 2 Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants are required to meet all the criteria below in order to be included in&#xD;
             the trial:&#xD;
&#xD;
               1. Male or female participants, aged 18 ~ 75 years.&#xD;
&#xD;
                  Confirmed diagnosis of advanced solid tumors by histological or cytological&#xD;
                  examination, Participants have no effective standard anticancer therapy available&#xD;
                  or is intolerant to standard anticancer therapy. For Part 1 Dose Ascending Stage,&#xD;
                  and Part 2 Dose expansion Stage:&#xD;
&#xD;
                  For Part 1: Advanced solid tumors including basal cell carcinoma and&#xD;
                  medulloblastoma, regardless of SMO or Gli1 alteration status.&#xD;
&#xD;
                  For Part 2: Participants will be enrolled into cohort A and cohort B. Cohort A:&#xD;
                  Participants with Adenocarcinoma of Esophagogastric Junction with SMO or Gli1&#xD;
                  protein overexpression alteration. (IHC≥1%) Cohort B: Participants with basal&#xD;
                  cell carcinoma, small cell lung cancer, neuroendocrine neoplasm and glioblastoma&#xD;
                  with SMO or Gli1 protein overexpression alteration. (IHC≥1%)&#xD;
&#xD;
               2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
               3. Participants with at least 1 measurable tumor lesion based on response evaluation&#xD;
                  criteria in solid tumors 1.1 (RECIST 1.1) and response assessment in&#xD;
                  neuro-oncology criteria (RANO) (participants with glioblastoma must accept skull&#xD;
                  MRI scanning.)&#xD;
&#xD;
               4. Recovery from past medical history of adverse reactions (excluding alopecia and&#xD;
                  neurotoxicity) caused by radiotherapy and chemotherapy to national cancer&#xD;
                  institute common terminology criteria for adverse events 4.03 (NCI CTCAE 4.03)&#xD;
                  ≤Grade 1 or baseline level.&#xD;
&#xD;
               5. Life expectancy &gt; 12 weeks.&#xD;
&#xD;
               6. Adequate organ function, defined by the following laboratory results, to be&#xD;
                  obtained prior to registration and enrollment:&#xD;
&#xD;
                  Bone marrow function: absolute neutrophil count (ANC)≥1.5×10^9/L; hemoglobin&#xD;
                  (HB)≥90 g/L; Platelet count (PLT)≥75×10^9/L.&#xD;
&#xD;
                  Liver function: Alanine aminotransferase (ALT)≤2.5×the upper limit of normal&#xD;
                  (ULN), aspartate aminotransferase (AST)≤2.5×ULN, alkaline phosphatase&#xD;
                  (ALP)≤2.5×ULN, total bilirubin (TBIL)≤1.5×ULN; ALT≤5×ULN, AST≤5×ULN, ALP≤5×ULN&#xD;
                  (For participants with liver metastasis).&#xD;
&#xD;
                  Renal function: creatinine≤1.5×ULN; clearance (CL)≥ 60 mL/min. Coagulation&#xD;
                  function: international normalized ratio (INR)≤1.5×ULN, activated partial&#xD;
                  thromboplastin time (APTT)≤1.5×ULN.&#xD;
&#xD;
                  Left ventricular ejection fractions (LVEF)≥50%. Creatine kinase (CK)≤2.5×ULN.&#xD;
&#xD;
               7. Participants (including partners) have no gestation plans and must use reliable&#xD;
                  methods of contraception during the study and until 8 months following the last&#xD;
                  dose of investigational product.&#xD;
&#xD;
               8. Participants must provide a written dated Informed Consent Form (ICF) with&#xD;
                  signature prior to screening.&#xD;
&#xD;
               9. Participants must be willing and able to adhere to the visit schedule and&#xD;
                  protocol requirements and be available to complete the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligible participants must not meet any of the following exclusion criteria:&#xD;
&#xD;
               1. Participants who have intracranial tumor and/or brain metastases with clinical&#xD;
                  symptoms and need treatment are ineligible except for the following&#xD;
                  circumstances:&#xD;
&#xD;
                    1. recovery from the therapy (including radiotherapy and/or surgery) 4 weeks&#xD;
                       before enrollment.&#xD;
&#xD;
                    2. Participants with intracranial tumor who are clinically stable during&#xD;
                       screening and enrollment, have no need to medication by hormone or&#xD;
                       anticonvulsants, and are estimated to be clinically stable during the study.&#xD;
&#xD;
               2. Participants with glioblastoma confirmed diagnosis via MRI or CT of intracranial&#xD;
                  hemorrhage and intratumor hemorrhage.&#xD;
&#xD;
               3. Participants with positive human immunodeficiency virus(HIV) or hepatitis C virus&#xD;
                  antibody (HCV) or hepatitis B surface antigen (HBV DNA&gt;2.0 ×103 IU/ml) or active&#xD;
                  infections which require systematic antibiotics therapy or concurred with&#xD;
                  unexplainable fever before drug treatment.&#xD;
&#xD;
               4. History of pulmonary fibrosis or interstitial pneumonia including pneumoconiosis&#xD;
                  and radiation pulmonary fibrosis beyond radiation field.&#xD;
&#xD;
               5. Participants with dysphagia.&#xD;
&#xD;
               6. Participants with incontrollable hydrops in third lumen such as malignant pleural&#xD;
                  effusion and ascites.&#xD;
&#xD;
               7. Participants with Diarrhea &gt; Grade 2 (according to CTCAE 4.03)&#xD;
&#xD;
               8. Any clinically significant gastrointestinal abnormalities, which may impair&#xD;
                  absorption of ZSP1602, such as Crohn's disease, ulcerative colitis and subtotal&#xD;
                  gastrectomy.&#xD;
&#xD;
               9. Participants with major surgery or active peptic ulcer disease or unrecovered&#xD;
                  wound.&#xD;
&#xD;
              10. History of myocardial infarction or congestive heart-failure (CHF) at NYHA≥3&#xD;
                  level within 6 months prior to enrollment.&#xD;
&#xD;
              11. Has either a history of uncontrollable or unstable angina pectoris or a history&#xD;
                  of severe or uncontrollable ventricular arrhythmia.&#xD;
&#xD;
              12. Participants with QTcF prolongations in electrocardiogram (ECG) baseline&#xD;
                  (QTcF&gt;450ms for males or QTcF&gt;470ms for females) or with high risk factors&#xD;
                  leading to QT intervals prolonging (including hypokalemia, familial QT interval&#xD;
                  prolongation syndrome).&#xD;
&#xD;
              13. Participants with concomitant illness such as hemorrhagic or thrombotic diseases&#xD;
                  or with anticoagulant treatment in routine dose for the moment.&#xD;
&#xD;
              14. Participants with medications known to be moderate and strong inhibitors or&#xD;
                  inducers of CYP3A4 during screening and that cannot be discontinued before&#xD;
                  starting treatment with ZSP1602.&#xD;
&#xD;
              15. History of most recently chemotherapy, radiotherapy, or non-antibody antitumor&#xD;
                  biologics within 4 weeks prior to the first ZSP1602 treatment and last time&#xD;
                  medication of nitrosoureas, mitomycin C or doxorubicin within 6 weeks and latest&#xD;
                  usage of antibody antitumor biologics within 8 weeks.&#xD;
&#xD;
              16. History of autoimmune disease.&#xD;
&#xD;
              17. History of allergic reactions to ZSP1602, any of the excipients of ZSP1602 or&#xD;
                  similar compounds.&#xD;
&#xD;
              18. Pregnant or nursing women.&#xD;
&#xD;
              19. Participants who, in the judgment of the investigator, will be unfit for the&#xD;
                  study. ( For reasons such as poor compliance, unsuitable for venous&#xD;
                  catheterization and so on)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Cheng, MD</last_name>
    <phone>+8643185871902</phone>
    <email>jl.cheng@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Chang Chun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengying, MD</last_name>
      <email>jl.cheng@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

